# 2025年11月3日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 论指南的未来

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41176597](https://pubmed.ncbi.nlm.nih.gov/41176597)
**期刊：** Critical care (London, England)
**PMID：** 41176597
**DOI：** 10.1186/s13054-025-05731-x

### 第一部分 原文与翻译

**英文原标题：** On the future of guidelines.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本文可能是一篇关于临床指南未来发展方向的社论或观点性文章。基于文章标题推断，作者旨在探讨在重症医学领域，临床实践指南所面临的挑战与机遇，例如如何整合人工智能、大数据等新兴技术，以及如何提高指南的实用性和临床依从性。尽管该文章没有提供摘要，无法得知其具体论证和结论，但它很可能为未来指南的制定和更新提供了前瞻性的思考和方向性建议，对临床决策者和研究者具有重要的启发意义。

---

## 2. 围手术期卡瑞利珠单抗联合利伐西尼对比单纯手术治疗具有中高复发风险的可切除肝细胞癌患者（CARES-009）：一项随机化2/3期试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41125112](https://pubmed.ncbi.nlm.nih.gov/41125112)
**期刊：** Lancet (London, England)
**PMID：** 41125112
**DOI：** 10.1016/S0140-6736(25)01720-9

### 第一部分 原文与翻译

**英文原标题：** Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.

**英文摘要原文：**
BACKGROUND: Surgical resection is the preferred curative approach for patients with early-stage hepatocellular carcinoma, but recurrence remains a major challenge. Consequently, neoadjuvant and adjuvant therapies have been proposed to reduce tumour burden and mitigate the risk of recurrence. The CARES-009 trial aimed to evaluate perioperative camrelizumab plus rivoceranib in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence.

METHODS: This multicentre, open-label, randomised, phase 2/3 trial enrolled patients with hepatocellular carcinoma classified as China Liver Cancer Staging (CNLC) stage Ib-IIIa without Vp4 portal vein tumour thrombosis (corresponding to Barcelona Clinic Liver Cancer stage A with tumour >5 cm, stage B, or stage C without Vp4 involvement or extrahepatic metastasis) at 16 hospitals in China. Patients were randomly assigned (1:1) to receive perioperative therapy or surgery alone and were stratified by CNLC stage and hepatitis B virus (HBV) infection status. The perioperative group received two cycles of neoadjuvant camrelizumab plus rivoceranib, followed by surgery and adjuvant camrelizumab plus rivoceranib. The primary endpoint was event-free survival (EFS) and was assessed by investigators (who were not masked to group assignment) in the intention-to-treat population. Safety was evaluated in the as-treated population. This trial is registered with ClinicalTrials.gov (NCT04521153) and is ongoing.

FINDINGS: Between March 25, 2021, and Jan 29, 2024, 294 patients (87% male; 99% Han Chinese) were randomly assigned to the perioperative group (n=148) or surgery alone group (n=146). At a prespecified interim analysis, with a median follow-up of 21·3 months, median EFS was 42·1 months (95% CI 23·2-not estimable [NE]) in the perioperative group versus 19·4 months (14·9-NE) in the surgery alone group (hazard ratio 0·59, 95% CI 0·41-0·85; p=0·0040). Grade 3 or worse treatment-related adverse events occurred in 53 (38%) patients in the perioperative group and no patients in the surgery alone group. Two treatment-related deaths occurred during neoadjuvant therapy in the perioperative group: one due to hepatic failure, assessed as possibly related to treatment, and one due to combined hepatic and renal failure, with the causality deemed indeterminate.

INTERPRETATION: Perioperative camrelizumab plus rivoceranib significantly improved EFS compared with surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence.

FUNDING: Shanghai Hospital Development Center and Jiangsu Hengrui Pharmaceuticals.

**中文摘要译文：**
背景：手术切除是早期肝细胞癌患者的首选根治性治疗方法，但术后复发仍是一项重大挑战。因此，学界提出了新辅助和辅助治疗方案，旨在减少肿瘤负荷并降低复发风险。CARES-009试验旨在评估围手术期使用卡瑞利珠单抗联合利伐西尼治疗具有中高复发风险的可切除肝细胞癌患者的疗效。

方法：这项多中心、开放标签、随机化的2/3期试验在中国16家医院入组了经中国肝癌分期（CNLC）评定为Ib-IIIa期且无Vp4门静脉癌栓的肝细胞癌患者（相当于巴塞罗那临床肝癌分期中肿瘤>5 cm的A期、B期，或无Vp4累及或肝外转移的C期）。患者按1:1的比例被随机分配至围手术期治疗组或单纯手术组，并根据CNLC分期和乙型肝炎病毒（HBV）感染状态进行分层。围手术期治疗组接受了两个周期的新辅助卡瑞利珠单抗联合利伐西尼治疗，随后进行手术，术后再接受辅助卡瑞利珠单抗联合利伐西尼治疗。主要终点是无事件生存期（EFS），由研究者（未对分组情况设盲）在全分析人群（intention-to-treat）中进行评估。安全性在按治疗方案处理的人群（as-treated）中进行评估。该试验已在ClinicalTrials.gov注册（注册号：NCT04521153），目前仍在进行中。

结果：在2021年3月25日至2024年1月29日期间，共294名患者（87%为男性；99%为汉族）被随机分配至围手术期治疗组（n=148）或单纯手术组（n=146）。在一次预设的中期分析中，中位随访时间为21.3个月，围手术期治疗组的中位EFS为42.1个月（95% CI 23.2-无法评估[NE]），而单纯手术组为19.4个月（14.9-NE）（风险比为0.59，95% CI 0.41-0.85；p=0.0040）。围手术期治疗组中有53名（38%）患者出现了3级或以上级别的治疗相关不良事件，而单纯手术组中则没有患者出现。在围手术期治疗组的新辅助治疗期间，发生了两起与治疗相关的死亡事件：一例死于肝功能衰竭，被评估为可能与治疗相关；另一例死于肝肾联合衰竭，其因果关系被判定为不确定。

结论：对于具有中高复发风险的可切除肝细胞癌患者，与单纯手术相比，围手术期使用卡瑞利珠单抗联合利伐西尼能显著改善其无事件生存期。

资金来源：上海市医院发展中心和江苏恒瑞医药股份有限公司。

### 第二部分 AI 大师评价

该研究是一项关键的2/3期随机对照试验，旨在探索围手术期卡瑞利珠单抗（PD-1抑制剂）联合利伐西尼（TKI）对比单纯手术对中高危复发风险可切除肝细胞癌的疗效。研究结果表明，该联合疗法显著延长了患者的无事件生存期（42.1个月 vs 19.4个月），为解决肝癌术后高复发率这一临床难题提供了强有力的循证医学证据。这项发现具有改变临床实践的潜力，可能将围手术期免疫联合靶向治疗确立为该类患者的新标准治疗模式，但同时也需关注其带来的3级以上不良事件风险。

---

## 3. 依沃西单抗联合化疗对比替雷利珠单抗联合化疗作为晚期鳞状非小细胞肺癌一线治疗的随机、双盲、3期临床试验 (HARMONi-6)

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41125109](https://pubmed.ncbi.nlm.nih.gov/41125109)
**期刊：** Lancet (London, England)
**PMID：** 41125109
**DOI：** 10.1016/S0140-6736(25)01848-3

### 第一部分 原文与翻译

**英文原标题：** Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.

**英文摘要原文：**
BACKGROUND: Squamous non-small-cell lung cancer (NSCLC) is associated with worse clinical outcomes than non-squamous NSCLC, but treatment options are scarce. We aimed to evaluate the efficacy and safety of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as a first-line therapy for patients with advanced squamous NSCLC.

METHODS: We conducted a randomised, double-blind, phase 3 trial at 50 sites across China (HARMONi-6). Patients aged 18-75 years with previously untreated, pathologically confirmed, unresectable stage IIIB, IIIC, or stage IV squamous NSCLC and an Eastern Cooperative Oncology Group performance status score of 0 or 1 were eligible for inclusion. Patients were randomly assigned (1:1) to receive intravenous ivonescimab (20 mg/kg) or tislelizumab (200 mg), plus intravenous paclitaxel (175 mg/m) and carboplatin (area under the curve 5 mg/mL per min) once every 3 weeks for four cycles, followed by ivonescimab (20 mg/kg) or tislelizumab (200 mg) monotherapy as maintenance treatment for up to 24 months. Randomisation was stratified by disease stage (IIIB or IIIC vs IV) and PD-L1 tumour proportion score (≥1% vs <1%). The primary endpoint was progression-free survival assessed by the independent radiographic review committee as per Response Evaluation Criteria in Solid Tumours guidelines (version 1.1) in all randomly assigned patients. Safety, defined as adverse events and serious adverse events related to treatment, as well as adverse events related to immunity or VEGF blockade, were analysed in all randomly assigned patients who received at least one dose of the assigned study treatment. This study is registered at ClinicalTrial.gov (NCT05840016), has completed enrolment, and is ongoing for treatment and follow-up.

FINDINGS: From Aug 17, 2023, to Jan 21, 2025, 761 patients were screened for eligibility, among whom 532 (70%) patients were enrolled and randomly assigned to receive ivonescimab plus chemotherapy (266 [50%] patients) or tislelizumab plus chemotherapy (266 [50%] patients). As of Feb 28, 2025, median follow-up time was 10·3 months (95% CI 9·5-11·0). Median progression-free survival was 11·1 months (95% CI 9·9-not evaluable) in the ivonescimab group and 6·9 months (5·8-8·6) in the tislelizumab group (hazard ratio 0·60 [95% CI 0·46-0·78]; one-sided p<0·0001). The progression-free survival benefit with ivonescimab plus chemotherapy was consistent regardless of PD-L1 status. 170 (64%) patients in the ivonescimab group and 144 (54%) patients in the tislelizumab group had grade 3 or higher treatment-related adverse events, with grade 3 or higher immune-related adverse events occurring in 24 (9%) patients in the ivonescimab group and in 27 (10%) patients in the tislelizumab group. Grade 3 or higher treatment-related haemorrhage occurred in five (2%) patients in the ivonescimab group and in two (1%) patients in the tislelizumab group.

INTERPRETATION: In patients with untreated advanced squamous NSCLC, ivonescimab plus chemotherapy showed significantly improved progression-free survival compared with tislelizumab plus chemotherapy, regardless of PD-L1 status, as well as a manageable safety profile. This regimen could be used as a novel first-line treatment in this patient group.

FUNDING: Akeso Biopharma.

**中文摘要译文：**
背景: 与非鳞状非小细胞肺癌（NSCLC）相比，鳞状NSCLC的临床结局更差，但治疗选择稀少。本研究旨在评估依沃西单抗联合化疗对比替雷利珠单抗联合化疗作为晚期鳞状NSCLC患者一线治疗的疗效与安全性。

方法: 我们在中国50个研究中心开展了一项随机、双盲、3期临床试验（HARMONi-6）。符合入组条件的患者年龄为18-75岁，既往未经治疗、经病理学确诊的不可切除的IIIB、IIIC或IV期鳞状NSCLC，且美国东部肿瘤协作组（ECOG）体能状态评分为0或1分。患者按1:1的比例随机分配，接受静脉注射依沃西单抗（20 mg/kg）或替雷利珠单抗（200 mg），联合静脉注射紫杉醇（175 mg/m²）和卡铂（曲线下面积 5 mg/mL·min），每3周一次，共进行四个周期；随后接受依沃西单抗（20 mg/kg）或替雷利珠单抗（200 mg）单药维持治疗，最长可达24个月。随机化根据疾病分期（IIIB或IIIC期 vs IV期）和PD-L1肿瘤比例评分（≥1% vs <1%）进行分层。主要终点是由独立影像学审查委员会根据实体瘤疗效评价标准（1.1版）在所有随机分配患者中评估的无进展生存期。安全性分析在所有接受了至少一剂指定研究治疗的随机分配患者中进行，定义为与治疗相关的不良事件和严重不良事件，以及与免疫或VEGF阻断相关的不良事件。本研究已在ClinicalTrial.gov注册（NCT05840016），已完成患者招募，目前正在进行治疗和随访。

结果: 从2023年8月17日至2025年1月21日，共筛选了761名患者，其中532名（70%）患者被纳入并随机分配至依沃西单抗联合化疗组（266名[50%]患者）或替雷利珠单抗联合化疗组（266名[50%]患者）。截至2025年2月28日，中位随访时间为10.3个月（95% CI 9.5-11.0）。依沃西单抗组的中位无进展生存期为11.1个月（95% CI 9.9-不可评估），而替雷利珠单抗组为6.9个月（5.8-8.6）（风险比 0.60 [95% CI 0.46-0.78]；单侧p<0.0001）。无论PD-L1表达状态如何，依沃西单抗联合化疗均显示出一致的无进展生存期获益。依沃西单抗组有170名（64%）患者，替雷利珠单抗组有144名（54%）患者发生3级或以上治疗相关不良事件，其中3级或以上免疫相关不良事件在依沃西单抗组有24名（9%）患者发生，在替雷利珠单抗组有27名（10%）患者发生。依沃西单抗组有5名（2%）患者，替雷利珠单抗组有2名（1%）患者发生3级或以上治疗相关出血事件。

结论: 在未经治疗的晚期鳞状NSCLC患者中，与替雷利珠单抗联合化疗相比，依沃西单抗联合化疗显著改善了无进展生存期，且无论PD-L1表达状态如何均能获益，其安全性可控。该方案可作为此类患者群体的一种新的一线治疗选择。

资金来源: 康方生物。

### 第二部分 AI 大师评价

本研究是一项头对头比较新型PD-1/VEGF双特异性抗体依沃西单抗与PD-1抑制剂替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的3期临床试验。研究关键发现，依沃西单抗方案显著延长了患者的无进展生存期（11.1个月 vs 6.9个月），且疗效不受PD-L1表达水平影响，安全性可控。这项研究成果具有重要的临床价值，它首次证实了PD-1/VEGF双抗联合化疗优于PD-1单抗联合化疗的标准疗法，有望为晚期鳞状NSCLC患者提供一个更优效的一线治疗新标准。

---

## 4. 溶瘤VSV在CAR上的特异性装载可增强CAR-T细胞信号传导与抗肿瘤活性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40938370](https://pubmed.ncbi.nlm.nih.gov/40938370)
**期刊：** The Journal of experimental medicine
**PMID：** 40938370
**DOI：** 10.1084/jem.20241851

### 第一部分 原文与翻译

**英文原标题：** Specific loading of oncolytic VSV on CAR enhances CAR-T cell signaling and antitumor activity.

**英文摘要原文：**
Oncolytic viruses (OVs) have been shown to increase the efficacy of chimeric antigen receptor (CAR) T cells in treating solid tumors. However, their combined effect has been limited by the unbalanced distribution of two agents in tumor tissue and viral infection-mediated CAR-T cell exhaustion. Here, we designed a CAR moiety by inserting the CR2 and CR3 domains (CR2/3-CAR) of low-density lipoprotein receptor, which is the viral receptor of oncolytic vesicular stomatitis virus (VSV) mutant (VSVΔ51), enabling specific loading of VSVΔ51 onto CAR-T cells. The anchored VSVΔ51 could be released from CAR-T cells and efficiently delivered to tumor tissue. Further investigation revealed that the cross-connection between viral envelope proteins and CR2/3-CAR moieties facilitated forming antigen-free CAR clusters and antigen-induced CAR synapse, triggered CAR signaling transduction, and directly pre-activated the CAR-T cells. Consequently, this approach potently enhanced the proliferation, metabolic fitness, and immunological activities of CAR-T cells, and subsequently enhanced the OV/CAR-T synergetic cytotoxicity, revealing an effective strategy for treating solid tumors.

**中文摘要译文：**
研究表明，溶瘤病毒（OVs）能够提高嵌合抗原受体（CAR）T细胞治疗实体瘤的疗效。然而，由于两种制剂在肿瘤组织中分布不均以及病毒感染介导的CAR-T细胞耗竭，其联合效应受到了限制。在此，我们通过插入低密度脂蛋白受体的CR2和CR3结构域（CR2/3-CAR），设计了一种CAR结构，该受体是溶瘤性水泡性口炎病毒（VSV）突变体（VSVΔ51）的病毒受体，从而实现了VSVΔ51在CAR-T细胞上的特异性装载。锚定的VSVΔ51可以从CAR-T细胞上释放，并被高效递送至肿瘤组织。进一步研究发现，病毒包膜蛋白与CR2/3-CAR结构之间的交联促进了无抗原CAR簇的形成和抗原诱导的CAR突触的形成，触发了CAR信号转导，并直接预激活了CAR-T细胞。因此，该方法有效增强了CAR-T细胞的增殖、代谢适应性和免疫活性，并继而增强了OV/CAR-T的协同细胞毒性作用，揭示了一种治疗实体瘤的有效策略。

### 第二部分 AI 大师评价

本研究旨在解决溶瘤病毒与CAR-T细胞联合疗法中药物分布不均及T细胞耗竭的核心难题。研究团队通过巧妙设计一种新型CAR（CR2/3-CAR），使其能够特异性“搭载”溶瘤性VSV病毒，实现了两者向肿瘤的协同递送。关键发现是，这种搭载不仅解决了递送问题，病毒与CAR的结合还能预激活CAR-T细胞，显著增强其抗肿瘤活性。这项研究将溶瘤病毒从单纯的“杀伤弹药”转变为CAR-T细胞的“激活增强剂”，为开发更高效的实体瘤细胞免疫疗法提供了极具创新性的策略和重要价值。

---

## 5. 显性负相ADA2突变导致杂合携带者出现ADA2缺乏症

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40864493](https://pubmed.ncbi.nlm.nih.gov/40864493)
**期刊：** The Journal of experimental medicine
**PMID：** 40864493
**DOI：** 10.1084/jem.20250499

### 第一部分 原文与翻译

**英文原标题：** Dominant negative ADA2 mutations cause ADA2 deficiency in heterozygous carriers.

**英文摘要原文：**
Human ADA2 deficiency (DADA2) is an inborn error of immunity with a broad clinical phenotype, which encompasses vasculopathy and hemato-immunological features. Diagnosis is based on the combination of decreased serum ADA2 activity and the identification of biallelic deleterious alleles in the ADA2 gene. DADA2 carriers harbor a single pathogenic variant in ADA2 and are mostly considered healthy and asymptomatic. Here, we report ten patients from seven kindreds presenting with a phenotype indicative of DADA2, in whom only a single pathogenic variant was identified. We investigated the effect of these and additional reported ADA2 missense variants on ADA2 protein expression, secretion, and enzymatic activity. Our studies indicate that p.G47A, p.G47R, p.G47V, p.R169Q, p.E328K, p.H424N, and p.Y453C exert a dominant negative effect on ADA2 enzymatic activity, dimerization, and/or secretion. We conclude that humans with heterozygous dominant negative missense variants in ADA2 are at risk of DADA2.

**中文摘要译文：**
人类ADA2缺乏症（DADA2）是一种先天性免疫缺陷病，具有广泛的临床表型，包括血管病变以及血液和免疫学特征。其诊断基于血清ADA2活性降低和鉴定出ADA2基因中的双等位基因有害性变异。DADA2携带者在ADA2基因中携带单个致病性变异，通常被认为是健康且无症状的。本研究中，我们报道了来自七个家系的十名患者，他们表现出提示DADA2的表型，但在他们体内仅鉴定出单个致病性变异。我们研究了这些以及其他已报道的ADA2错义变异对ADA2蛋白表达、分泌和酶活性的影响。我们的研究表明，p.G47A、p.G47R、p.G47V、p.R169Q、p.E328K、p.H424N和p.Y453C突变对ADA2的酶活性、二聚化和/或分泌产生显性负相效应。我们得出结论，携带ADA2基因杂合显性负相错义变异的个体存在罹患DADA2的风险。

### 第二部分 AI 大师评价

本研究旨在探究为何部分仅携带单个ADA2致病变异的杂合子会表现出典型的DADA2临床表型，从而挑战了该病传统的常染色体隐性遗传模式。研究通过功能实验证实，特定的ADA2错义突变具有显性负相效应，即突变蛋白会干扰野生型蛋白的正常功能（如二聚化或分泌），进而导致酶活性显著下降。这一发现不仅揭示了DADA2新的致病机制，也极大地拓展了其遗传学谱系，对该病的精准诊断、遗传咨询和未来治疗策略具有重要的指导意义。

---

速递结束，祝您工作愉快！